SOURCES SOUGHT
66 -- Reagent Kits for the Methylation Studies of Gynecological Cancers for the National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG)
- Notice Date
- 7/25/2013
- Notice Type
- Sources Sought
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- SS-NCI-130099-HN
- Archive Date
- 8/2/2013
- Point of Contact
- Huy Nguyen, Phone: 2402765570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
anh-huy.nguyen@nih.gov, ninans@mail.nih.gov
(anh-huy.nguyen@nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 325413 with a size standard of 500 employees is being considered. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ) through FedBizOpps. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG) conducts methylation studies of gynecological cancers. Specifically, the DCEG studies genome-wide gene methylation in gynecological cancers and normal tissues to identify important carcinogenic pathways and possible biomarkers for risk assessment and early detection. DNA methylation at specific genes has been widely recognized as an alternative mechanism of tumor suppressor gene inactivation. A number of other genes have been described to be methylated in gynecological cancers, suggesting that methylation of some of these genes may occur at precancerous stages and drive carcinogenesis. DNA methylation is increasingly being evaluated as a biomarker. Methylated DNA is a stable analyte that can be measured from a wide range of biospecimens. The Illumina Infinium methylation platform is the most widely used large-scale methylation platform. The assay has been used in the NCI-funded The Cancer Genome Atlas (TCGA) efforts of gynecological cancers. The NCI is currently using the platform to analyze methylation in gynecological cancers. The NCI is extending the work and need to be able to pool and combine the methylation data from the ongoing effort, the planned effort, and TCGA. Thus, it is important that the results are generated on the same platform. Further, only the Illumina Infinium platform has been validated for paraffin-embedded tissues and provides dedicated reagents to process this specimen type. The purpose of this contract is to procure Illumina brand reagent kits required by the NCI to continue the methylation studies of gynecological cancers. Contractor Requirements: •Four (4) Illumina InfiniumHD FFPE Restore Kit (#WG-321-1002) •One (1) Illumina Human Methylation 450 DNA Analysis Bead Chip Kit (96 samples) (#WG-314-1002) Delivery: •Within twelve (12) months from the date of award. How to Submit a Response: 1.Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2.Due Date: Capability statements are due no later than 4:00 a.m. EST on July 30, 2013. 3.Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Huy Nguyen, Contract Specialist at anh-huy.nguyen@nih.gov or mailed to the address located under Point of Contact. All questions must be in writing and can be faxed to (240) 276-5401 or emailed. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference number SS-NCI-130099-HN on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Huy Nguyen 9609 Medical Center Dr, Room 1E154 Bethesda, MD 20892-9705 anh-huy.nguyen@nih.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/SS-NCI-130099-HN/listing.html)
- Record
- SN03127466-W 20130727/130725235755-c53c5e00c189e668e0633dd1c536be14 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |